U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H30Cl2N10.2ClH
Molecular Weight 578.368
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORHEXIDINE HYDROCHLORIDE

SMILES

Cl.Cl.ClC1=CC=C(NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC2=CC=C(Cl)C=C2)C=C1

InChI

InChIKey=WJLVQTJZDCGNJN-UHFFFAOYSA-N
InChI=1S/C22H30Cl2N10.2ClH/c23-15-5-9-17(10-6-15)31-21(27)33-19(25)29-13-3-1-2-4-14-30-20(26)34-22(28)32-18-11-7-16(24)8-12-18;;/h5-12H,1-4,13-14H2,(H5,25,27,29,31,33)(H5,26,28,30,32,34);2*1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C22H30Cl2N10
Molecular Weight 505.447
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/019028s022lbl.pdf http://www.drugbank.ca/drugs/DB00878 http://www.wikidoc.org/index.php/Chlorhexidine_gluconate

Chlorhexidine is a broad-spectrum biocide effective against Gram-positive bacteria, Gram-negative bacteria and fungi. It is used primarily as its salts (e.g., the dihydrochloride, diacetate, and digluconate). Chlorhexidine inactivates microorganisms with a broader spectrum than other antimicrobials (e.g. antibiotics) and has a quicker kill rate than other antimicrobials (e.g. povidone-iodine). It has both bacteriostatic (inhibits bacterial growth) and bactericidal (kills bacteria) mechanisms of action, depending on its concentration. Chlorhexidine kills by disrupting the cell membrane. The most common side effects associated with chlorhexidine gluconate oral rinses are: 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception; 4) toothache; 5) upper respiratory tract infection; and 6) headache.

Originator

Curator's Comment: 1950s — Chlorhexidine is discovered by the Imperial Chemical Industries, Limited (Manchester, UK) while researching the synthesis of anti-malarial agents

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
HIBICLENS

Approved Use

Use for the preparation of the patient's skin prior to surgery. Helps to reduce bacteria that potentially can cause skin infection.

Launch Date

1976
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2007 μg/mL
2.5 mg single, dental
dose: 2.5 mg
route of administration: Dental
experiment type: SINGLE
co-administered:
CHLORHEXIDINE inflammatory exudate
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
0.206 μg/g
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORHEXIDINE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
148287.6 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORHEXIDINE saliva
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
180892.9 ng × h/mL
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
CHLORHEXIDINE saliva
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
187083.4 μg × h/mL
2.5 mg single, dental
dose: 2.5 mg
route of administration: Dental
experiment type: SINGLE
co-administered:
CHLORHEXIDINE inflammatory exudate
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
17%
CHLORHEXIDINE serum
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
73%
CHLORHEXIDINE saliva
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2 % 1 times / day single, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: single
Dose: 2 %, 1 times / day
Sources:
healthy, 18-64 years
Health Status: healthy
Age Group: 18-64 years
Sex: M+F
Sources:
Other AEs: Redness...
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
healthy, 18-79 years
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Sources:
Disc. AE: Papule, Erythema...
AEs leading to
discontinuation/dose reduction:
Papule
Erythema (grade 2)
Edema (grade 1)
Sources:
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
healthy, 22-60 years
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Sources:
Disc. AE: Burning sensation, Petechial rash...
AEs leading to
discontinuation/dose reduction:
Burning sensation (grade 1)
Petechial rash (grade 1)
Scab
Sources:
1.5 oz 1 times / day single, oral
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
healthy, child
Other AEs: Distress epigastric, Nausea...
Other AEs:
Distress epigastric
Nausea
Alcohol intoxication
Sources:
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Other AEs: Toothache, Upper respiratory tract infection...
Other AEs:
Toothache (50.7%)
Upper respiratory tract infection (28.4%)
Headache (27.1%)
Sinusitis (13.8%)
Influenza-like symptoms (7.6%)
Back pain (6.7%)
Tooth disorder (6.2%)
Bronchitis (6.2%)
Abscess (5.8%)
Pain (4.9%)
Allergy (4%)
Myalgia (4%)
Gum hyperplasia (3.6%)
Pharyngitis (3.6%)
Arthralgia (3.1%)
Dysmenorrhea (3.1%)
Dyspepsia (3.1%)
Rhinitis (2.7%)
Coughing (2.7%)
Arthrosis (2.7%)
Hypertension (2.2%)
Stomatitis ulcerative (2.2%)
Tendinitis (2.2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Redness grade 2
2 % 1 times / day single, topical
Recommended
Dose: 2 %, 1 times / day
Route: topical
Route: single
Dose: 2 %, 1 times / day
Sources:
healthy, 18-64 years
Health Status: healthy
Age Group: 18-64 years
Sex: M+F
Sources:
Papule Disc. AE
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
healthy, 18-79 years
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Sources:
Edema grade 1
Disc. AE
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
healthy, 18-79 years
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Sources:
Erythema grade 2
Disc. AE
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
healthy, 18-79 years
Health Status: healthy
Age Group: 18-79 years
Sex: M+F
Sources:
Scab Disc. AE
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
healthy, 22-60 years
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Sources:
Burning sensation grade 1
Disc. AE
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
healthy, 22-60 years
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Sources:
Petechial rash grade 1
Disc. AE
3 % 1 times / day multiple, topical
Recommended
Dose: 3 %, 1 times / day
Route: topical
Route: multiple
Dose: 3 %, 1 times / day
Sources:
healthy, 22-60 years
Health Status: healthy
Age Group: 22-60 years
Sex: M+F
Sources:
Alcohol intoxication
1.5 oz 1 times / day single, oral
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
healthy, child
Distress epigastric
1.5 oz 1 times / day single, oral
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
healthy, child
Nausea
1.5 oz 1 times / day single, oral
Studied dose
Dose: 1.5 oz, 1 times / day
Route: oral
Route: single
Dose: 1.5 oz, 1 times / day
Sources:
healthy, child
Sinusitis 13.8%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Hypertension 2.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Stomatitis ulcerative 2.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Tendinitis 2.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Arthrosis 2.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Coughing 2.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Rhinitis 2.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Headache 27.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Upper respiratory tract infection 28.4%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Arthralgia 3.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Dysmenorrhea 3.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Dyspepsia 3.1%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Gum hyperplasia 3.6%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Pharyngitis 3.6%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Allergy 4%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Myalgia 4%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Pain 4.9%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Abscess 5.8%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Toothache 50.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Bronchitis 6.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Tooth disorder 6.2%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Back pain 6.7%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
Influenza-like symptoms 7.6%
2.5 mg 3 times / month multiple, subgingival
Recommended
unhealthy, mean age 47 years
PubMed

PubMed

TitleDatePubMed
Cytotoxicity and genotoxicity of chlorhexidine on macrophages in vitro.
2014-04
Food components with anticaries activity.
2012-04
Identification and characterization of inhibitors of the aminoglycoside resistance acetyltransferase Eis from Mycobacterium tuberculosis.
2012-01-02
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011-07-14
Chlorhexidine-induced apoptosis or necrosis in L929 fibroblasts: A role for endoplasmic reticulum stress.
2009-01-15
[Ultrastructure study of pathogen of acanthamoeba keratitis].
2008-11
Adverse events associated with chlorhexidine use: results from the Department of Veterans Affairs Dental Diabetes Study.
2008-02
Cysticidal effect on acanthamoeba and toxicity on human keratocytes by polyhexamethylene biguanide and chlorhexidine.
2007-07
Chemoenzymatic synthesis and antimicrobial and haemolytic activities of amphiphilic bis(phenylacetylarginine) derivatives.
2006-10
Chlorhexidine in urethral gel: does it cause pain at flexible cystoscopy?
2006-04
Short-term side effects of 0.2% alcohol-free chlorhexidine mouthrinse used as an adjunct to non-surgical periodontal treatment: a double-blind clinical study.
2006-03
Remineralisation of carious enamel lesions after application of a CHX/F-mouthrinse compared with sole CHX- and placebo-application.
2006
Chlorhexidine induces DNA damage in rat peripheral leukocytes and oral mucosal cells.
2004-10
[Contact sensitization to pharmaceutic aids in dermatologic cosmetic and external use preparations].
2004-05
Effects of a chlorhexidine gluconate-containing mouthwash on the vitality and antimicrobial susceptibility of in vitro oral bacterial ecosystems.
2003-08
Probing depth changes following 2 years of periodontal maintenance therapy including adjunctive controlled release of chlorhexidine.
2003-04
Developing a dynamic pharmacophore model for HIV-1 integrase.
2000-06-01
Chlorhexidine and taste. Influence of mouthwashes concentration and of rinsing time.
2000-05
Severe anaphylaxis after a chlorhexidine bath.
1999-05
6-month use of 0.2% delmopinol hydrochloride in comparison with 0.2% chlorhexidine digluconate and placebo. (I). Effect on plaque formation and gingivitis.
1998-09
The effectiveness and side effects of 0.1% and 0.2% chlorhexidine mouthrinses: a clinical study.
1998-07
Clinical and pathological changes in the knee after accidental chlorhexidine irrigation during arthroscopy. Case reports and review of the literature.
1998-05
The activity of candidate virucidal agents, low pH and genital secretions against HIV-1 in vitro.
1995-07-01
Spermicides: anti-HIV activity and cytotoxicity in vitro.
1993-02
Effects of chlorhexidine diacetate on Candida albicans, C. glabrata and Saccharomyces cerevisiae.
1992-04
[Anaphylactic shock with ventricular fibrillation induced by chlorhexidine].
1992-03
Combined effects of Zn(2+)-chlorhexidine and Zn(2+)-cetylpyridinium chloride on caries incidence in partially desalivated rats.
1991-08
Bradycardia associated with chlorhexidine spray.
1989-06
Some toxic effects of lead, other metals and antibacterial agents on the nervous system--animal experiment models.
1984
[Disturbances of taste from oral disinfectants (author's transl)].
1978-10
Nephrotoxic and hepatotoxic effects of triclosan and chlorhexidine in rats.
1977-10
Further studies on effects of irrigation solutions on rat bladders.
1976-12
The effect of chlorhexidine irrigation of the bladder in the rat.
1975-10
Patents

Sample Use Guides

Recommended use is twice daily oral rinsing for 30 seconds, morning and evening after tooth brushing. Usual dosage is 15 ml (1 tablespoon) of undiluted Chlorhexidine gluconate oral rinse. Prophylaxis intervals - no longer than six months.
Route of Administration: Topical
In Vitro Use Guide
Curator's Comment: Chlorhexidine caused significant decreases in both total anaerobe and total aerobe/facultative anaerobe counts (P < 0.05), together with lesser decreases in gram-negative anaerobes.
Minimum bactericidal concentrations are different for different bacterial strains (3.9-83.3 mg/l).
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:34:12 GMT 2025
Edited
by admin
on Mon Mar 31 17:34:12 GMT 2025
Record UNII
E64XL9U38K
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORHEXIDINE HYDROCHLORIDE
GREEN BOOK   MART.   USAN   USP   WHO-DD  
USAN  
Official Name English
CHLORHEXIDINE DIHYDROCHLORIDE
EP   INCI   MI   WHO-IP  
INCI  
Preferred Name English
NSC-756679
Code English
CHLORHEXIDINE HYDROCHLORIDE [USAN]
Common Name English
CHLORHEXIDINE HYDROCHLORIDE [USP IMPURITY]
Common Name English
AY-5312
Code English
CHLORHEXIDINE DIHYDROCHLORIDE [MI]
Common Name English
1,1'-HEXAMETHYLENEBIS(5-(P-CHLOROPHENYL)BIGUANIDE)DIHYDROCHLORIDE
Common Name English
2,4,11,13-TETRAAZATETRADECANEDIIMIDAMIDE, N,N''-BIS(4-CHLOROPHENYL)-3,12-DIIMINO-, DIHYDROCHLORIDE
Common Name English
CHLORHEXIDINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
CHLORHEXIDINE HYDROCHLORIDE [MART.]
Common Name English
CHLORHEXIDINE DIHYDROCHLORIDE [WHO-IP]
Common Name English
CHLORHEXIDINE HYDROCHLORIDE [GREEN BOOK]
Common Name English
CHLORHEXIDINE HCL
Common Name English
Chlorhexidine hydrochloride [WHO-DD]
Common Name English
CHLORHEXIDINE DIHYDROCHLORIDE [EP MONOGRAPH]
Common Name English
CHLORHEXIDINE HYDROCHLORIDE [JAN]
Common Name English
DANTROCHE HIBITANE
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C28394
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
EPA PESTICIDE CODE 481700
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL790
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
MERCK INDEX
m3362
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY Merck Index
NSC
756679
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
CAS
3697-42-5
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
PUBCHEM
62517
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
RXCUI
2361
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY RxNorm
DAILYMED
E64XL9U38K
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
FDA UNII
E64XL9U38K
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
DRUG BANK
DBSALT001610
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
ECHA (EC/EINECS)
223-026-6
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
SMS_ID
100000092569
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
NCI_THESAURUS
C65314
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
EPA CompTox
DTXSID7047144
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
EVMPD
SUB01216MIG
Created by admin on Mon Mar 31 17:34:12 GMT 2025 , Edited by admin on Mon Mar 31 17:34:12 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
TITRATION
EP
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Description: A white or almost white, crystalline powder; odourless. Solubility: Sparingly soluble in water; soluble in 450 parts of ethanol (~750 g/l) TS. Category: Disinfectant. Storage: Chlorhexidine dihydrochloride should be kept in a well-closed container, protected from light.